ACASTI PHARMA INC.
Acasti Pharma Inc. is a biopharmaceutical company that focuses on developing and commercializing new prescription drugs for the treatment of cardiovascular diseases. The company is headquartered in Laval, Quebec, Canada, and was founded in 2002.
Acasti Pharma is focused on developing drugs that target high levels of triglycerides, a type of fat found in the blood that is linked to an increased risk of heart disease. The company's lead product candidate, CaPre (omega-3 phospholipid), is a patented omega-3 fatty acid formulation that is designed to reduce triglyceride levels in patients with hypertriglyceridemia.
CaPre is derived from krill oil, a source of omega-3 fatty acids that has been shown to have superior bioavailability and absorption compared to other sources of omega-3 fatty acids, such as fish oil. The drug has demonstrated significant reductions in triglyceride levels in clinical trials and has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of familial chylomicronemia syndrome (FCS), a rare genetic disorder that causes severe hypertriglyceridemia.
Acasti Pharma is also developing other omega-3 fatty acid-based products for the treatment of cardiovascular diseases, including a combination of CaPre and a statin for the treatment of high cholesterol and a medical food for the treatment of fatty liver disease.
The global market for hypertriglyceridemia drugs is expected to reach $4.2 billion by 2026, according to a report by ResearchAndMarkets.com. With its focus on developing innovative drugs for the treatment of cardiovascular diseases, Acasti Pharma is well-positioned to capitalize on this growing market.
Acasti Pharma is led by a team of experienced executives with a strong track record of success in drug development and commercialization. The company's management team has extensive experience in the biopharmaceutical industry, and is committed to delivering value to its shareholders through a disciplined investment approach.
Acasti Pharma is a biopharmaceutical company that is focused on developing and commercializing new prescription drugs for the treatment of cardiovascular diseases. With its lead product candidate CaPre and a strong pipeline of other omega-3 fatty acid-based products, the company is well-positioned to drive growth in the years ahead.